Once-daily single-tablet regimens: A long and winding road to excellence in antiretroviral treatment

AIDS Reviews

Volumn 14, Issue 3, 2012, Pages 168-178

  Llibre, Josep M ^a,b   Clotet, Bonaventura ^c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c IrsiCaixa Foundation   (Spain)

Author keywords

Antiretroviral agents; Antiretroviral therapy; Combination; Drug therapy; Highly active; HIV infection

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; COBICISTAT; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; GS 7340; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; METHADONE; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; PLACEBO; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; TENOFOVIR; TENOFOVIR PLUS ABACAVIR PLUS LAMIVUDINE; TENOFOVIR PLUS EMTRICITABINE PLUS LAMIVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABNORMAL DREAMING; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRACTICE GUIDELINE; QT PROLONGATION; RASH; REVIEW; SOMNOLENCE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; OXAZINES; PATIENT SATISFACTION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84864670297     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes J, Cayla J. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30:105-10. (Pubitemid 34506694)
2. + cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med. 2003;139:810-16.
3. Bangsberg D, Perry S, Charlebois E, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-3. (Pubitemid 32549871)
4. Paterson D, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. (Pubitemid 30432540)
5. Parienti J, Bangsberg D, Verdon R, Gardner E. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48:484-8.
6. Walensky R, Paltiel A, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11-19.
7. Lima V, Hogg R, Harrigan P, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21:685-92. (Pubitemid 46568625)
8. Llibre J, Schapiro J, Clotet B. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis. 2010;50:872-81.
9. Charpentier C, Lambert-Niclot S, Larrouy L, et al. Evolution of the K65R, K103N and M184V/I Reverse Transcriptase Mutations Prevalence in HIV-1-infected Patients Experiencing Virologic Failure between 2005 and 2010. In: 19TH CROI. Seattle, WA, 2012. [Abstract 726].
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. March 3, 2012; 1-239. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. [Accessed: April 3, 2012].
11. Llibre J, Arribas J, Domingo P, et al. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS. 2011;25:1683-90.
12. Bangalore S, Kamalakkannan G, Parkar S, Messerli F. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-19. (Pubitemid 47176510)
13. European AIDS Clinical Society (EACS) Guidelines. Clinical Management and Treatment of HIV Infected Adults in Europe. Version 6-0. October 2011. Available at: http://europeanaidsclinicalsociety.org/. [Accessed January 12, 2012].
14. National Consensus Document by GESIDA/National Aids Plan on Antiretroviral Treatment in Adults Infected by the Human Immunodeficiency Virus (January 2012 Update). Available at: http://www.gesida.seimc.org. [Accessed Jan 12, 2012].
15. Boyd S. Management of HIV infection in treatment-naive patients: a review of the most current recommendations. Am J Health Syst Pharm. 2011;68:991-1001.
16. Sax P, Meyers J, Mugavero M, Davis K. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7:e31591.
17. Bangsberg D, Ragland K, Monk A, Deeks S. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24:2835-40.
18. Cohen C, Davis K, Meyers J. Association between daily antiretroviral pill burden and hospitalization risk in a Medicaid population with HIV. In: 51st ICAAC, 2011. Chicago, Illinois, USA. [Abstract H2-791].
19. Daar E, Tierney C, Fischl M, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445-56.
20. Sax P, Tierney C, Collier A, et al. Abacavir-lamivudine versus tenofoviremtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230-40.
21. Sax P, Tierney C, Collier A, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191-201.
22. Smith K, Patel P, Fine D, et al. Randomized, double-blind, placebomatched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-56.
23. Post F, Moyle G, Stellbrink H, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010; 55:49-57.
24. Gallant J, Dejesus E, Arribas J, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60. (Pubitemid 43113030)
25. Pozniak A, Gallant J, Dejesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-40. (Pubitemid 44885619)
26. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201. (Pubitemid 38917996)
27. Molina J, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646-55.
28. Lennox J, Dejesus E, Lazzarin A, et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
29. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22:1389-97.
30. Gazzard B, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
31. Blasco A, Arribas J, Boix V, et al. [Costs and cost efficacy analysis of preferred GESIDA regimens in 2012 for initial antiretroviral therapy]. Enferm Infecc Microbiol Clin. 2012;30:283-93.
32. Molina J, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-46.
33. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439-48.
34. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir- boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429-38.
35. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-63. (Pubitemid 38496486)
36. Cooper D, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010;201:803-13.
37. Cohen C, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378:229-37.
38. Shionogi ViiV Healthcare. Initial data from pivotal phase III study of dolutegravir in HIV.Issued April 2, 2012. Available at: http://www.gsk.com/ media/pressreleases/2012/2012-pressrelease-1013597.htm.
39. Riddler S, Haubrich R, DiRienzo A, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106. (Pubitemid 351679596)
40. +<200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr. 2010;53:582-8.
41. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-73.
42. Robbins G, De Gruttola V, Shafer R, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-303. (Pubitemid 37509737)
43. Arribas J, Pulido F, Miro J, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). AIDS. 2002;16:1554-6. (Pubitemid 34804222)
44. Pulido F, Arribas J, Miro J, et al. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr. 2004;35:343-50. (Pubitemid 38332794)
45. Miro J, Manzardo C, Pich J, et al. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. AIDS Res Hum Retroviruses. 2010;26:747-57.
46. Llibre J, Santos J, Puig T, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother. 2008;62:909-13.
47. Scourfield A, Zheng J, Chinthapalli S, et al. Discontinuation of Atripla(R) as first-line therapy in HIV-1 infected individuals. AIDS. 2012;26(11):1399-401.
48. Crauwels H, van Heeswijk R, Kestens D, et al. The pharmacokinetic interaction between omeprazole and TMC278, an investigational NNRTI. 9th International Congress on Drug Therapy in HIV Infection. 2008. Glasgow, UK. [Abstract 239].
49. Crauwels H, van Heeswijk R, Bollen A, et al. The effect of different types of food on the bioavailability of TMC278, an investigational NNRTI. 9th International Workshop on Pharmacology of HIV Therapy, 2008. New Orleans, USA. [Abstract 32].
50. Pozniak A, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55-65.
51. FDA Label for Rilpivirine. Available at: http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm. [Accessed April 27, 2012].
52. Cohen C, Molina J, Cassetti I, et al. Pooled week 96 efficacy, resistance and safety results from the double-blind, randomised, phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatmentnaïve, HIV-1-infected adults. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 2011. [Abstract TULBPE032].
53. Tebas P. Results from the pooled DEXA substudies of the double-blind, randomised, phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naive, HIV-infected adults. 13th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. Rome, Italy. 2011. [Oral 23].
54. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59:39-46.
55. Centre for Drug Evaluation and Research. Addendum to ONDQA Biopharmaceutics Review of Rilpivirine. Application number 202022Orig1s000. Page 383. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 202022Orig1s000ClinPharmR.pdf. [Accessed April 26, 2012].
56. Rimsky L, Voronin E, Eron L, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients failing rilpivirine (RPV, TMC278) in the Phase III studies ECHO and THRIVE: 48 week analysis. 20th International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, Mexico, 2011. [Abstract 9].
57. Anta L, Llibre J, Poveda E, et al. Rilpivirine resistance mutations in HIV- 1 infected patients failing NNRTI therapy in the Drug Resistance Database of the Spanish AIDS Research Network (RIS). 19th CROI. Seattle, WA, USA. 2012. [Abstract 710].
58. Hu Z, Kuritzkes D. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol. 2011;85:11309-14.
59. Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther. 2012;17:439-46.
60. German P, Warren D, West S, Hui J, Kearney B. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55:323-9.
61. Mathias A, German P, Murray B, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87:322-9.
62. Xu L, Liu H, Murray B, et al. Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010;1:209-13.
63. Lepist E, Murray B, Tong L, Roy A, Bannister R, Ray A. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. 51st ICAAC. 2011. Chicago, IL, USA. [Abstract A1-1724].
64. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS. 2011;25:1881-6.
65. Dejesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43:1-5. (Pubitemid 44306480)
66. Zolopa A, Berger D, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;201:814-22.
67. Molina J, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012;12:27-35.
68. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25:F7-12.
69. Soriano V, Cox J, Eron J, et al. Dolutegravir treatment of HIV subjects with raltegravir resistance: viral suppression at week 24 in the VIKING study. 13th European AIDS Conference. 2011. Serbia, Belgrade. [Abstract PS1/2].
70. Ramanathan S, Wang H, Custodio J, et al. Pharmacokinetics of EVG/COBI/FTC/TDF single tablet regimen following treatment with EFV/FTC/TDF (Atripla) in healthy subjects. 13th International Workshop on Clinical Pharmacology of HIV Therapy, 2012, Barcelona. [Abstract O-21].
71. Phase 3b open label study to evaluate switching from regimens consisting of a non-nucleoside reverse transcriptase inhibitor plus emtricitabine and tenofovir DF to the elvitegravir/cobicistat/emtricitabine/tenofovir DF single-tablet regimen in virologically suppressed, HIV-1 infected patients. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01495702.
72. Ruane P, Dejesus E, Berger D, et al. GS-7340 25 mg and 40 mg demonstrate greater antiviral activity compared with TDF 300 mg in a 10-day monotherapy study of HIV-1 infected patients. 19th CROI. 2012. Seattle, WA, USA. [Abstract 103].
73. Markowitz M, Zolopa A, Ruane P, et al. GS-7340 demonstrates greater declines in HIV-1 RNA than tenofovir disoproxil fumarate during 14 days of monotherapy in HIV-1 infected subjects. 18th CROI. 2011. Boston, MA, USA. [Abstract 152LB].
74. Lee W, He G, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898-906. (Pubitemid 40631605)
75. Ramanathan S, Wei L, Custodio J, et al. Pharmacokinetics of a novel EVG/COBI/FTC/GS-7340 single tablet regimen. 13th International Workshop on Clinical Pharmacology of HIV Therapy. 2012, Barcelona. [Abstract O-13].
76. Min S, Sloan L, Dejesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25:1737-45.
77. van Lunzen J, Maggiolo F, Arribas J, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111-18.
78. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254-8.
79. Kakuda T, Opsomer M, Timmers M, et al. Bioavailability of two FDC formulations of darunavir/cobicistat 800/150mg compared with darunavir/ritonavir 800/100mg co-administered as single agents. 13th International Workshop on Clinical Pharmacology of HIV Therapy, 2012. Barcelona, Spain. [Abstract O 20].
80. Matias A, Liu H, Warren D, Sekar V, Kearney B. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir. 11th International Workshop on Clinical Pharmacology and HIV Therapy. 2010. Sorrento. [Abstract 28].
81. Safety and efficacy of darunavir/cobicistat/emtricitabine/GS-7340 single tablet regimen versus cobicistat-boosted darunavir plus emtricitabine/tenofovir disoproxil fumarate fixed dose combination in HIV-1 infected, antiretroviral treatment naive adults. Available at: http://clinicaltrials.gov/ct2/show/ NCT01565850. [Accessed April 26, 2012].
82. Mills A, Cohen C, Dejesus E, et al. Switching from efavirenz/ emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single tablet regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjects. 51st ICAAC. 2011. Chicago, IL, USA. [Abstract H2-794c].
83. Jackson A, Moyle G, Watson V, et al. Tenofovir (TFV), emtricitabine (FTC) intracellular (IC) and plasma, and efavirenz (EFV) plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. 19th CROI. Seattle, WA, USA. 2012. [Abstract 585].
84. Garcia-Lerma J, Aung W, Cong M, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol. 2011;85:6610-17.
85. Birkus G, Wang R, Liu X, et al. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother. 2007;51:543-50. (Pubitemid 46188294)